You are here

EMPEROR Preserved Study

Thursday, 30 September 2021, 16:15 - 17:15, Athens Hall

Chair: F. Zannad, FR

J. Butler, US: EMPEROR-Preserved: context, design and population

S.D. Anker, DE: EMPEROR-Preserved: main results

G. Filippatos, GR: New data from EMPEROR-Preserved: patient population, efficacy endpoints and safety of empagliflozin in patients with and without diabetes

M. Packer, US: Pooled-Analysis of EMPEROR-Reduced and EMPEROR-Preserved trials: key results

A. Norhammar, SE: Commentary

Group Discussion